If you or a patient on Tysabri is experiencing new neurological symptoms like confusion, vision changes, or weakness, it's important to consider the rare but serious risk of progressive multifocal leukoencephalopathy (PML). This page provides clinicians and patients with essential information on PML symptoms, monitoring protocols, and risk stratification, drawing on established medical guidelines and recent research.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically only occurs in patients who are immunocompromised, and has occurred in patients who have received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three factors are known to increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals should monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, memory impairment, cognitive disorder, and balance disorder. These symptoms overlap with common adverse events reported in FDA FAERS data for Tysabri, which include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and mobility decreased (3,769 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). This overlap can make early diagnosis challenging, as PML symptoms may be mistaken for multiple sclerosis relapse or other Tysabri-related effects. Diagnosis of PML requires a high index of suspicion and typically involves brain MRI showing characteristic white matter lesions, detection of JCV DNA in cerebrospinal fluid, and brain biopsy in some cases. The boxed warning emphasizes that because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients are monitored regularly and that PML is detected as early as possible.
The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is an alpha-4 integrin antagonist that inhibits the migration of lymphocytes into the brain. This reduces the immune surveillance of the central nervous system, allowing JCV to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to JCV and potential for reactivation. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed in the 1,869 patients with multiple sclerosis who were treated for a median of 120 weeks; these two patients had received Tysabri in addition to interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The third case occurred after eight doses in one of the 1,043 patients with Crohn's disease who were evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These cases highlight that PML can occur even within the first two years of treatment, though risk increases with longer duration.
For patients who develop PML, the prognosis is poor, with the infection usually leading to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Management involves immediate discontinuation of Tysabri and consideration of plasma exchange to accelerate drug clearance, along with supportive care and treatment of immune reconstitution inflammatory syndrome (IRIS) that may occur when immune function returns. The adequacy of warnings regarding Tysabri and PML is a critical risk consideration. The boxed warning clearly states the increased risk, identifies known risk factors, and mandates monitoring and immediate withholding of the drug at the first sign of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients and healthcare providers must be vigilant, as early symptoms of PML can be subtle and may be attributed to the underlying disease. The TOUCH program is intended to mitigate this risk through regular monitoring, but it does not eliminate the possibility of PML.
Attorney-related considerations for affected patients include the potential for legal claims if inadequate warnings or failure to monitor contributed to harm. Patients who develop PML after Tysabri treatment may seek legal counsel to evaluate whether the risks were properly communicated and whether appropriate monitoring occurred. The timeline between exposure and documented harm is variable; PML can occur after a few months to several years of treatment, with risk increasing after 2 years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who develop PML should document their treatment history, including dates of Tysabri administration, any prior immunosuppressant use, and results of anti-JCV antibody testing. In summary, Tysabri is associated with a well-documented risk of PML, a severe and often fatal brain infection. The drug's labeling includes a boxed warning, risk factor identification, and monitoring requirements. Patients and healthcare providers must remain alert for early signs of PML, and affected individuals may benefit from legal consultation to assess their options.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn's disease. It carries a boxed warning stating that it increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus that often leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Three known risk factors increase the risk of PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond 2 years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Symptoms of PML include progressive neurological deficits such as weakness, gait disturbance, memory impairment, cognitive disorder, and balance disorder. These can overlap with common Tysabri side effects, making early diagnosis challenging (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).
Diagnosis requires a high index of suspicion and typically involves brain MRI showing characteristic white matter lesions, detection of JCV DNA in cerebrospinal fluid, and sometimes brain biopsy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Patients may seek legal counsel to evaluate whether inadequate warnings or failure to monitor contributed to harm. Documenting treatment history, including dates of Tysabri administration and prior immunosuppressant use, is important for potential claims.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.